Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TMC207 added to background regimen for multidrug-resistant pulmonary tuberculosis
2011-000653-23Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multidrug-resistant tuberculosis (MDR-TB) and pulmonary tuberculosis (TB) comparing Bedaquiline + background regimen with Placebo + background regimen (2 arms). Primary endpoint: Number of patients with favorable treatment outcome at Week 60. Started May 2012; status: terminated.
02
Drugs
bedaquiline
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on 2011-000653-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000653-23.